Based on these data, there is a compelling need to explore resistance mechanisms associated with anti-HER2 therapy and to establish rational strategies to improve trastuzumab efficacy in HER2-positive GC patients [19,20,21,22,23,24,25,26,27,28]. This evidence concerns the gene ERBB2 and gastric cancer.